Trial Outcomes & Findings for Actigraphic Analysis of Treatment Response (NCT NCT00723580)

NCT ID: NCT00723580

Last Updated: 2015-08-18

Results Overview

The child's impulsivity and inability to sleep represented a significant symptom and risk factor. Impulsivity and sleep will be actigraphically assessed by treatment conditions.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

1 participants

Primary outcome timeframe

May 12- July 14, 2010

Results posted on

2015-08-18

Participant Flow

A six year old child with Autism Spectrum Disorder (pervasive developmental disorder) and Kabuki Syndrome anticipating a pharmacological intervention was evaluated for sleep and behavioral disturbances. She was invited to participate, her parents provided consent and the child acknowledged her assent.

The child had previously not responded to multiple medication trials, was stimulated by diphenylhydramine, over-sedated on clonidine and had mood destabilization when tried on mirtazapine. The child received no medication for the month preceding the initiation of the study.

Participant milestones

Participant milestones
Measure
Actigraphic (Activity Count) Measurement of Sleep and Activity
Actigraphic measurements obtained by attaching an actigraphic watch device to the child's non-dominant wrist obtain measurements that occur every thirty seconds for a duration of approximately 21 days. These measurements reflect treatment condition sleep characteristics where sleep is indicated by activity counts below 40. Three 21 day actigraphic measurement periods occurred with the initial measurement occurring through baseline period and the period in which the child's pharmacological treatment was initiated. The second and third, 21 day periods of Actigraphic measurement occurred at 22 and 23 months from baseline. Five treatment conditions during the measurement periods including 1. baseline no medication 2. risperidone .25 mg at bedtime for 7 days (q.h.s.) 3. risperidone twice daily (b.i.d.) 4. risperidone .25 mg three times a day (t.i.d.) and 5. risperidone .50 mg three times a day (t.i.d.)
Overall Study
STARTED
1
Overall Study
Baseline Measurements
1
Overall Study
COMPLETED
1
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Actigraphic Analysis of Treatment Response

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Actigraphic (Activity Count) Measurement of Sleep and Activity
n=1 Participants
Actigraphic measurements obtained by attaching an actigraphic watch device to the child's non-dominant wrist obtain measurements that occur every thirty seconds for a duration of approximately 21 days. These measurements reflect treatment condition sleep characteristics where sleep is indicated by activity counts below 40. Three 21 day actigraphic measurement periods occurred with the initial measurement occurring through baseline period and the period in which the child's pharmacological treatment was initiated. The second and third, 21 day periods of Actigraphic measurement occurred at 22 and 23 months from baseline. Five treatment conditions during the measurement periods including 1. baseline no medication 2. risperidone .25 mg at bedtime for 7 days (q.h.s.) 3. risperidone twice daily (b.i.d.) 4. risperidone .25 mg three times a day (t.i.d.) and 5. risperidone .50 mg three times a day (t.i.d.)
Age, Continuous
6 years
STANDARD_DEVIATION 0 • n=99 Participants
Sex: Female, Male
Female
1 Participants
n=99 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
Region of Enrollment
United States
1 participants
n=99 Participants
Age, Categorical
<=18 years
1 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants

PRIMARY outcome

Timeframe: May 12- July 14, 2010

Population: Single subject repeated Actigraphic(at thirty second intervals), observational (every two months) and psychometric (baseline and at 23 months) measurements of a child anticipating pharmacological treatment. Actigraphic measurements (three 21 day periods) over five treatment conditions that included a non-medication baseline and spanned 23 months.

The child's impulsivity and inability to sleep represented a significant symptom and risk factor. Impulsivity and sleep will be actigraphically assessed by treatment conditions.

Outcome measures

Outcome measures
Measure
Actigraphic (Activity Count) Measurement of Sleep and Activity
n=191235 Activity counts
Actigraphic measurements obtained by attaching an actigraphic watch device to the child's non-dominant wrist obtain measurements that occur every thirty seconds for a duration of approximately 21 days. These measurements reflect treatment condition sleep characteristics where sleep is indicated by activity counts below 40. Three 21 day actigraphic measurement periods occurred with the initial measurement occurring through baseline period and the period in which the child's pharmacological treatment was initiated. The second and third, 21 day periods of Actigraphic measurement occurred at 22 and 23 months from baseline. Five treatment conditions during the measurement periods including 1. baseline no medication 2. risperidone .25 mg at bedtime for 7 days (q.h.s.) 3. risperidone twice daily (b.i.d.) 4. risperidone .25 mg three times a day (t.i.d.) and 5. risperidone .50 mg three times a day (t.i.d.)
Actigraphic Measurement of Treatment Conditions
risperidone .5 mg t.i.d. Midnight to 1:00 AM
9.94 activity
Standard Deviation 51.651
Actigraphic Measurement of Treatment Conditions
Baseline No Medication Midnight to 1:00 AM
55.02 activity
Standard Deviation 206.432

SECONDARY outcome

Timeframe: May-7-2008 to July -14-2010

The Systematic Observation Scale utilizes single-subject repeated measurements. Symptoms and issues of interest are defined and a variety of frequency and sampling methods can be applied. The Systematic Observation Scale was designed so Primary Observers (parents, guardians, self observers or others) can make pre-treatment and subsequent observations to track, document and evaluate symptom variation over the course of an illness. The measurement utilized is the percentage of time the symptom is observed by the primary observer since the previous observation.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: May-7-2008 to July -14-2010

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: May-7-2008 to July -14-2010

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: May-7-2008 to July -14-2010

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: May-7-2008 to July -14-2010

This scale measures general personality adjustment reflecting a dimension associated with highly adaptive to maladaptive adjustment. The Personality Inventory for Children (PIC) is an age and gender referenced objective multidimensional measurement of affect, behavior, ability and family function. The PIC was administered prior to treatment with risperidone and repeated after 22 months of treatment. The PIC serves as both an actuarial pre-treatment diagnostic tool as well as a post-treatment repeated measurement indicating treatment and developmentally associated change.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: May-7-2008 to July -14-2010

The factors that underlie this scale are academic ability, poor achievement, impulsivity, limited concentration and over or under-assertiveness with peers. The Personality Inventory for Children (PIC) is an age and gender referenced objective multidimensional measurement of affect, behavior, ability and family function.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: May-7-2008 to July -14-2010

The factors that underlie this scale are fatigue, aches and pains, insomnia, somatic response to stress and malingering. The Personality Inventory for Children (PIC) is an age and gender referenced objective multidimensional measurement of affect, behavior, ability and family function.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: May 7, 2008-July 14,2010

The factors that underlie this scale are poor frustration tolerance, irritability, sadness, lack of interest, hostility,limited social participation and resistance to authority. The Personality Inventory for Children (PIC) is an age and gender referenced objective multidimensional measurement of affect, behavior, ability and family function.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: May-7-2008 to July -14-2010

The factors that underlie this scale are physical isolation, Shyness, isolation from peers, emotional distance and isolated intellectual interests. The Personality Inventory for Children (PIC) is an age and gender referenced objective multidimensional measurement of affect, behavior, ability and family function

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: May-7-2008 to July -14-2010

The factors that underlie this scale are social success, social rejection, adults as only social contacts, and the ability to lead and follow. The Personality Inventory for Children (PIC) is an age and gender referenced objective multidimensional measurement of affect, behavior, ability and family function.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: May-7-2008 to July -14-2010

The factors that underlie this scale are family stability, inter-parent communication, presence of love and happiness in the home and appropriateness of discipline. The Personality Inventory for Children (PIC) is an age and gender referenced objective multidimensional measurement of affect, behavior, ability and family function.

Outcome measures

Outcome data not reported

Adverse Events

Actigraphic (Activity Count) Measurement of Sleep and Activity

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Bill J. Duke, Ph.D.

Child Psychopharmacology Institute

Phone: 701-241-9281

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place